These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36831424)

  • 1. Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy.
    Poullenot F; Laharie D
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatment.
    Laharie D
    Dig Dis; 2014; 32 Suppl 1():116-21. PubMed ID: 25531363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
    Poullenot F; Amiot A; Nachury M; Viennot S; Altwegg R; Bouhnik Y; Abitbol V; Nancey S; Vuitton L; Peyrin-Biroulet L; Biron A; Fumery M; Picon L; Vidon M; Reenaers C; Serrero M; Savoye G; Beaugerie L; Rivière P; Laharie D
    J Crohns Colitis; 2022 Nov; 16(10):1523-1530. PubMed ID: 35512337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge.
    Ferretti F; Cannatelli R; Maconi G; Ardizzone S
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy.
    Hasan B; Tandon KS; Miret R; Khan S; Riaz A; Gonzalez A; Rahman AU; Charles R; Narula N; Castro FJ
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1016-1021. PubMed ID: 35191100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Previous Cancer/Lymphoma and Refractory Inflammatory Bowel Disease.
    Bernheim O; Axelrad J; Itzkowitz SH; Colombel JF
    Dig Dis; 2015; 33 Suppl 1():44-49. PubMed ID: 26367257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.
    Poullenot F; Seksik P; Beaugerie L; Amiot A; Nachury M; Abitbol V; Stefanescu C; Reenaers C; Fumery M; Pelletier AL; Nancey S; Peyrin-Biroulet L; Bourreille A; Hébuterne X; Brixi H; Savoye G; Lourenço N; Altwegg R; Buisson A; Cazelles-Boudier C; Racine A; Vergniol J; Laharie D;
    Inflamm Bowel Dis; 2016 Jun; 22(6):1362-9. PubMed ID: 26919458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of inflammatory bowel disease patients with a cancer history.
    Beaugerie L
    Curr Drug Targets; 2014; 15(11):1042-8. PubMed ID: 25146698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
    Peyrin-Biroulet L; Rahier JF; Kirchgesner J; Abitbol V; Shaji S; Armuzzi A; Karmiris K; Gisbert JP; Bossuyt P; Helwig U; Burisch J; Yanai H; Doherty GA; Magro F; Molnar T; Löwenberg M; Halfvarson J; Zagorowicz E; Rousseau H; Baumann C; Baert F; Beaugerie L;
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):771-788.e10. PubMed ID: 36152897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer and immunomodulators in inflammatory bowel diseases.
    Biancone L; Onali S; Petruzziello C; Calabrese E; Pallone F
    Inflamm Bowel Dis; 2015 Mar; 21(3):674-98. PubMed ID: 25545375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
    Vedamurthy A; Gangasani N; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.
    Kalman RS; Hartshorn K; Farraye FA
    Inflamm Bowel Dis; 2015 Feb; 21(2):428-35. PubMed ID: 25251059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
    Moscicki AB; Flowers L; Huchko MJ; Long ME; MacLaughlin KL; Murphy J; Spiryda LB; Gold MA
    J Low Genit Tract Dis; 2019 Apr; 23(2):87-101. PubMed ID: 30907775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous cancer and/or lymphoma in patients with refractory IBD--con: anti-TNF or conventional immunosuppressive treatment.
    Mantzaris GJ
    Dig Dis; 2014; 32 Suppl 1():122-7. PubMed ID: 25531364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
    Cosnes J
    Dig Dis; 2017; 35(1-2):50-55. PubMed ID: 28147366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
    Khan N; Vallarino C; Lissoos T; Darr U; Luo M
    Drugs Aging; 2017 Nov; 34(11):859-868. PubMed ID: 29170864
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.